[{"id":"b69db9ce-f937-45b1-a3cb-3720a59cf8f0","acronym":"","url":"https://clinicaltrials.gov/study/NCT05702645","created_at":"2023-12-28T15:17:12.831Z","updated_at":"2025-02-25T14:52:26.613Z","phase":"","brief_title":"A Study to Learn More About the Health of Persons With Down Syndrome After Treatment for Acute Leukemia","source_id_and_acronym":"NCT05702645","lead_sponsor":"Children's Oncology Group","biomarkers":" CDKN2A • GATA3 • ARID5B","pipe":"","alterations":" ","tags":["CDKN2A • GATA3 • ARID5B"],"overall_status":"Recruiting","enrollment":" Enrollment 330","initiation":"Initiation: 11/30/2023","start_date":" 11/30/2023","primary_txt":" Primary completion: 06/30/2029","primary_completion_date":" 06/30/2029","study_txt":" Completion: 06/30/2029","study_completion_date":" 06/30/2029","last_update_posted":"2025-02-13"},{"id":"bd0915a0-fd20-4277-b54e-97bf1a6410c3","acronym":"","url":"https://clinicaltrials.gov/study/NCT03452774","created_at":"2021-01-18T17:01:36.578Z","updated_at":"2024-07-02T16:35:14.464Z","phase":"","brief_title":"SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry","source_id_and_acronym":"NCT03452774","lead_sponsor":"Massive Bio, Inc.","biomarkers":" EGFR • HER-2 • PD-L1 • KRAS • BRAF • ER • ALK • TP53 • TMB • FLT3 • ABL1 • NRAS • BRCA1 • BRCA2 • FGFR2 • PTEN • ROS1 • IDH1 • NTRK1 • BCL2 • IDH2 • NTRK3 • NTRK2 • STK11 • NPM1 • HRAS • DNMT3A • ERBB3 • RB1 • CLDN18 • PDGFRA • NF1 • JAK2 • NRG1 • POLE • AKT1 • PD-1 • CCND1 • MCL1 • KDR • PBRM1 • BAP1 • VEGFA • BCL6 • PDGFRB • PTCH1 • FGFR4 • MSH6 • CDK4 • MSH2 • CTNNB1 • MAP2K2 • FBXW7 • WT1 • ATRX • BRCA • RAF1 • TSC2 • CHEK2 • PD-L2 • ERBB4 • JAK1 • FANCA • TSC1 • MDM4 • POLD1 • CDK6 • CEBPA • PARP1 • AURKA • JAK3 • RICTOR • CHEK1 • GATA6 • MSH3 • TGFBR2 • GNAS • MYCL • AKT2 • CCND2 • CCND3 • CSF1R • MAP3K1 • ERCC4 • HDAC1 • PRDM1 • ZNF217 • CDKN1A • GATA3 • PARP2 • PARP3 • SDHA • ACVR1B • ZNF703","pipe":" | ","alterations":" HER-2 mutation • BAP1 mutation • AKT1 mutation • FGFR3 fusion • JAK3 mutation","tags":["EGFR • HER-2 • PD-L1 • KRAS • BRAF • ER • ALK • TP53 • TMB • FLT3 • ABL1 • NRAS • BRCA1 • BRCA2 • FGFR2 • PTEN • ROS1 • IDH1 • NTRK1 • BCL2 • IDH2 • NTRK3 • NTRK2 • STK11 • NPM1 • HRAS • DNMT3A • ERBB3 • RB1 • CLDN18 • PDGFRA • NF1 • JAK2 • NRG1 • POLE • AKT1 • PD-1 • CCND1 • MCL1 • KDR • PBRM1 • BAP1 • VEGFA • BCL6 • PDGFRB • PTCH1 • FGFR4 • MSH6 • CDK4 • MSH2 • CTNNB1 • MAP2K2 • FBXW7 • WT1 • ATRX • BRCA • RAF1 • TSC2 • CHEK2 • PD-L2 • ERBB4 • JAK1 • FANCA • TSC1 • MDM4 • POLD1 • CDK6 • CEBPA • PARP1 • AURKA • JAK3 • RICTOR • CHEK1 • GATA6 • MSH3 • TGFBR2 • GNAS • MYCL • AKT2 • CCND2 • CCND3 • CSF1R • MAP3K1 • ERCC4 • HDAC1 • PRDM1 • ZNF217 • CDKN1A • GATA3 • PARP2 • PARP3 • SDHA • ACVR1B • ZNF703"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 mutation • BAP1 mutation • AKT1 mutation • FGFR3 fusion • JAK3 mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 50000","initiation":"Initiation: 01/01/2018","start_date":" 01/01/2018","primary_txt":" Primary completion: 12/01/2026","primary_completion_date":" 12/01/2026","study_txt":" Completion: 06/01/2027","study_completion_date":" 06/01/2027","last_update_posted":"2024-03-15"},{"id":"02cdfb98-f9b7-4482-b0ad-47b025d97235","acronym":"","url":"https://clinicaltrials.gov/study/NCT04962529","created_at":"2021-07-15T13:06:04.923Z","updated_at":"2024-07-02T16:36:05.698Z","phase":"","brief_title":"Breast Cancer Liquid Biopsy Trial","source_id_and_acronym":"NCT04962529","lead_sponsor":"Anthony Magliocco","biomarkers":" HER-2 • ER • NKX2-1 • GATA3","pipe":" | ","alterations":" HER-2-H","tags":["HER-2 • ER • NKX2-1 • GATA3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2-H"],"overall_status":"Recruiting","enrollment":" Enrollment 450","initiation":"Initiation: 09/28/2020","start_date":" 09/28/2020","primary_txt":" Primary completion: 06/30/2023","primary_completion_date":" 06/30/2023","study_txt":" Completion: 07/31/2023","study_completion_date":" 07/31/2023","last_update_posted":"2022-08-11"},{"id":"78a03bb0-c80a-4fe2-a62d-1901f63a2029","acronym":"","url":"https://clinicaltrials.gov/study/NCT04966975","created_at":"2021-07-19T14:52:34.631Z","updated_at":"2024-07-02T16:36:27.775Z","phase":"","brief_title":"Effect and Prognosis of Immunohistochemical Biomarkers Changes in Patients With Bladder Cancer After Neoadjuvant Chemotherapy","source_id_and_acronym":"NCT04966975","lead_sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","biomarkers":" GATA3","pipe":"","alterations":" ","tags":["GATA3"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 09/01/2021","start_date":" 09/01/2021","primary_txt":" Primary completion: 08/31/2022","primary_completion_date":" 08/31/2022","study_txt":" Completion: 08/31/2022","study_completion_date":" 08/31/2022","last_update_posted":"2021-07-19"},{"id":"783c2f96-ba30-478f-862b-676b7775d699","acronym":"","url":"https://clinicaltrials.gov/study/NCT02451488","created_at":"2021-01-18T11:45:13.513Z","updated_at":"2024-07-02T16:36:50.247Z","phase":"Phase 4","brief_title":"Neoadjuvant Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in Cutaneous Stage L-lll Melanoma","source_id_and_acronym":"NCT02451488","lead_sponsor":"Mayo Clinic","biomarkers":" CSF2 • GATA3","pipe":" | ","alterations":" CSF2 expression","tags":["CSF2 • GATA3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CSF2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Leukine (sargramostim)"],"overall_status":"Completed","enrollment":" Enrollment 8","initiation":"Initiation: 05/01/2015","start_date":" 05/01/2015","primary_txt":" Primary completion: 11/04/2016","primary_completion_date":" 11/04/2016","study_txt":" Completion: 11/04/2016","study_completion_date":" 11/04/2016","last_update_posted":"2020-02-10"},{"id":"fdc507d0-755f-4c09-bf49-649c6f8e28f9","acronym":"","url":"https://clinicaltrials.gov/study/NCT00923845","created_at":"2021-01-18T03:34:37.540Z","updated_at":"2024-07-02T16:37:17.437Z","phase":"Phase 2","brief_title":"Low-Intensity Stem Cell Transplantation With Multiple Lymphocyte Infusions to Treat Advanced Kidney Cancer","source_id_and_acronym":"NCT00923845","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD8 • CD4 • FOXP3 • GATA3","pipe":"","alterations":" ","tags":["CD8 • CD4 • FOXP3 • GATA3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • temsirolimus • sirolimus • pentostatin • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 25","initiation":"Initiation: 03/01/2008","start_date":" 03/01/2008","primary_txt":" Primary completion: 06/01/2015","primary_completion_date":" 06/01/2015","study_txt":" Completion: 06/22/2017","study_completion_date":" 06/22/2017","last_update_posted":"2017-09-29"},{"id":"08338ec0-6078-48e0-bc33-7c4d40eba740","acronym":"MEL58","url":"https://clinicaltrials.gov/study/NCT01585350","created_at":"2021-01-18T06:45:23.070Z","updated_at":"2024-07-02T16:37:29.831Z","phase":"Phase 1","brief_title":"A Multipeptide Vaccine Plus Toll-Like Receptor Agonists in Melanoma Patients","source_id_and_acronym":"NCT01585350 - MEL58","lead_sponsor":"Craig L Slingluff, Jr","biomarkers":" MYD88 • CD8 • IFNG • TNFA • CXCL12 • CXCL9 • CD4 • CD69 • IL2 • CXCL13 • IL10 • CCL19 • FOXP3 • IL17A • IL23A • CCL21 • GATA3 • IL4 • IL5","pipe":"","alterations":" ","tags":["MYD88 • CD8 • IFNG • TNFA • CXCL12 • CXCL9 • CD4 • CD69 • IL2 • CXCL13 • IL10 • CCL19 • FOXP3 • IL17A • IL23A • CCL21 • GATA3 • IL4 • IL5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Hiltonol (poly-ICLC)"],"overall_status":"Completed","enrollment":" Enrollment 53","initiation":"Initiation: 10/01/2012","start_date":" 10/01/2012","primary_txt":" Primary completion: 07/01/2014","primary_completion_date":" 07/01/2014","study_txt":" Completion: 10/01/2014","study_completion_date":" 10/01/2014","last_update_posted":"2016-08-12"}]